Truist raised the firm’s price target on Kymera Therapeutics (KYMR) to $68 from $53 and keeps a Buy rating on the shares. The firm has updated its model to reflect $1.9B in peak adjusted sales estimated for KT-621s, reflecting increased conviction for KT-621 program over longer term and Phase 1b data readout expected over the near-term, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $70 from $60 at H.C. Wainwright
- Kymera Therapeutics: Promising Developments and Buy Rating Amidst Significant Clinical Advancements
- Kymera Therapeutics to present on KT-621 at EADV Congress
- Kymera Therapeutics initiated with an Overweight at Barclays
- Kymera Therapeutics initiated with an Outperform at RBC Capital